Literature DB >> 34857894

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.

Kathryn I Sunthankar1, Matthew T Jenkins2, Candace H Cote3, Sweta B Patel4, Robert S Welner4, P Brent Ferrell5.   

Abstract

Mutations in isocitrate dehydrogenase 2 (IDH2) have been noted to impact cellular differentiation in addition to DNA and histone methylation. However, little is known about the impact of IDH2 mutations on intracellular signaling. Using an isogenic cell line model, we investigated both differentiation and signaling responses in IDH2 mutant cells and show augmented responses to inflammatory immune ligands. Using phospho-specific flow and mass cytometry, we demonstrate IDH2 mutant cells were significantly more sensitive to IL-1β at multiple downstream readouts. Further, bulk RNA sequencing confirmed increases in cytokine-related signaling pathways and NF-κB target genes. Single-cell RNA sequencing of unstimulated and stimulated cells confirmed altered IL-1β transcriptional responses in the IDH2 mutant cells. Targeted inhibition of the IKK complex reduced IL-1β responses and induced cell death in primary IDH-mutated leukemia samples. Together, these results confirm altered IL-1β signaling in IDH2 mutant cells and identify this pathway as a potential therapeutic target.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34857894      PMCID: PMC9066619          DOI: 10.1038/s41375-021-01487-9

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  45 in total

1.  Inhibition of mutant IDH1 in acute myeloid leukaemia.

Authors:  Farhat Yaqub
Journal:  Lancet Oncol       Date:  2014-11-28       Impact factor: 41.316

2.  Tet2 restrains inflammatory gene expression in macrophages.

Authors:  Alyssa H Cull; Brooke Snetsinger; Rena Buckstein; Richard A Wells; Michael J Rauh
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

Review 3.  2-Oxoglutarate-dependent dioxygenases in cancer.

Authors:  Julie-Aurore Losman; Peppi Koivunen; William G Kaelin
Journal:  Nat Rev Cancer       Date:  2020-10-21       Impact factor: 60.716

4.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Authors:  Nikesh Kotecha; Nikki J Flores; Jonathan M Irish; Erin F Simonds; Debbie S Sakai; Sophie Archambeault; Ernesto Diaz-Flores; Marc Coram; Kevin M Shannon; Garry P Nolan; Mignon L Loh
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

5.  An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis.

Authors:  Samuel O Abegunde; Rena Buckstein; Richard A Wells; Michael J Rauh
Journal:  Exp Hematol       Date:  2017-11-28       Impact factor: 3.084

6.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Authors:  Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti
Journal:  Nat Med       Date:  2015-01-19       Impact factor: 87.241

Review 7.  Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.

Authors:  Francine E Garrett-Bakelman; Ari M Melnick
Journal:  Epigenomics       Date:  2016-07-19       Impact factor: 4.357

Review 8.  Isocitrate dehydrogenase mutations in myeloid malignancies.

Authors:  B C Medeiros; A T Fathi; C D DiNardo; D A Pollyea; S M Chan; R Swords
Journal:  Leukemia       Date:  2016-10-10       Impact factor: 11.528

9.  GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Authors:  Eric Padron; Jeffrey S Painter; Sateesh Kunigal; Adam W Mailloux; Kathy McGraw; Jessica M McDaniel; Eunhee Kim; Christopher Bebbington; Mark Baer; Geoffrey Yarranton; Jeffrey Lancet; Rami S Komrokji; Omar Abdel-Wahab; Alan F List; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2013-04-30       Impact factor: 25.476

Review 10.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Authors:  A P Im; A R Sehgal; M P Carroll; B D Smith; A Tefferi; D E Johnson; M Boyiadzis
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 12.883

View more
  1 in total

Review 1.  IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders.

Authors:  Ya Qi Gong; Shuang Wei; Yuan Yun Wei; Yong Lin Chen; Jian Cui; Yue Qiu Yu; Xiang Lin; Hong Xia Yan; Hui Qin; Lan Yi
Journal:  Oncol Lett       Date:  2022-06-24       Impact factor: 3.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.